The largest database of trusted experimental protocols

Azm198

Manufactured by AstraZeneca
Sourced in Sweden

AZM198 is a laboratory instrument designed for automated cell culture and sample processing. It features precise liquid handling, temperature control, and integrated imaging capabilities to support a range of cell-based assays and workflows. The core function of AZM198 is to provide a versatile and standardized platform for researchers to streamline their experimental processes.

Automatically generated - may contain errors

2 protocols using azm198

1

Neutrophil Isolation and MPO Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
BSH was purchased from Carbosynth Ltd (Compton, UK). HOCl was a commercial chlorine bleach product sold by Pental (Melbourne, Australia).Hank's balanced salt solution (HBSS) and phosphate buffered saline (PBS for cell culture, glucose oxidase (GO) from Aspergillus niger (≥100,000 U/g), N‐ethylmaleimide (NEM), 1,4‐dithiothreitol (DTT), taurine, 3,3′,5,5′‐tetramethylbenzidine (TMB), diphenylene iodonium chloride (DPI), sodium azide, bovine liver catalase, lysostaphin from Staphylococcus staphylolyticus, chloramphenicol and D‐(+)‐xylose were purchased from Sigma (Merck, Darmstadt, Germany). Roswell Park Memorial Institute 1640 medium (RPMI,Gibco), Lysogeny broth (LB; Miller's) and tryptic soy broth (TSB) powder were from Thermo Fisher (Waltham, MA, USA), and saponin was from Fluka (Buchs, Switzerland). MPO, from human neutrophils, was supplied by PLANTA (Vienna, Austria) and had a purity index (A430/A280) of at least 0.82. Dextran from Leucononstoc mesenteroides (average molecular weight: 150,000 Da; Sigma) and Ficoll‐Paque (GE Healthcare, Uppsala, Sweden, and Freiburg, Germany) were used for neutrophil isolation. The specific MPO inhibitors TX1 and AZM198, 2‐thioxanthine molecules,33 were provided by AstraZeneca (Mölndal, Sweden).
+ Open protocol
+ Expand
2

Evaluating MPO Inhibitor AZM198 in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
MPO inhibitor AZM198 (AstraZeneca, Mölndal, Sweden) was administered ad libitum in chow at a concentration expected to yield a daily dose of 500 µmol/kg and a plasma concentration of 2 µmol/L, estimated to inhibit extracellular MPO activity by >90%. Inhibitor vs. control treatment was started at the day of MI or sham operation (d0) in 8- to 12-week-old C57BL/6J WT mice. Adequate exposure was confirmed by mass spectrometry quantification of AZM198 in whole blood, drawn at 8 a.m. and 5 p.m. after 3 days of feeding in a pilot study and after 21 days of feeding in the main study (data not shown).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!